Physician profile
Labib Hashimi
NPI 1508847625
$30,791.67
in general payments reported to CMS, 2019-2025
80 companies · $3,979 in 2025
The $3,979 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,288 · 2020: $7,265 · 2021: $1,596 · 2022: $5,509 · 2023: $3,883 · 2024: $5,272 · 2025: $3,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $1,138 · Education: $837 · Honoraria: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,799.41 |
| Consulting Fee | $1,137.50 |
| Education | $836.51 |
| Honoraria | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $5,643.34 | 2020 | |
| Pharmacosmos Therapeutics INC. | $3,691.90 | 2022-2025 | Monoferric |
| Astrazeneca Pharmaceuticals Lp | $2,005.33 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Janssen Biotech, INC. | $1,988.97 | 2019-2025 | Darzalex, Imbruvica, Talvey |
| Partner Therapeutics, INC. | $1,802.25 | 2019 | |
| Incyte Corporation | $1,553.24 | 2019-2025 | Jakafi, Jakafi, Monjuvi |
| Pfizer INC. | $844.59 | 2019-2025 | |
| Celgene Corporation | $818.06 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| E.R. Squibb & Sons, L.L.C. | $770.04 | 2019-2024 | Reblozyl, Opdivo, Opdualag |
| Astellas Pharma US INC | $654.38 | 2020-2025 | Padcev, Xospata, Vyloy |
| Beigene USA, INC. | $525.28 | 2020-2025 | Brukinsa |
| Eisai INC. | $521.88 | 2019-2025 | |
| Sobi, INC | $499.58 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $482.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $481.47 | 2021-2025 |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $475.67 | 2020-2025 | Verzenio, Jaypirca |
| Daiichi Sankyo INC. | $445.27 | 2022-2025 | Datroway, Vanflyta, Enhertu |
| Glaxosmithkline, LLC. | $431.25 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $430.89 | 2022-2025 | Ninlaro, Iclusig, Alunbrig |
| Amgen INC. | $408.15 | 2020-2023 | Lumakras, Nplate |
| Abbvie INC. | $407.22 | 2021-2025 | |
| Gilead Sciences, INC. | $404.40 | 2021-2024 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $347.59 | 2019-2023 | Imbruvica |
| Pharmaessentia USA Corporation | $344.83 | 2022-2025 | Besremi |
| Genentech USA, INC. | $339.62 | 2019-2025 | Tecentriq, Polivy, Tecentriq Hybreza |
| Genzyme Corporation | $277.88 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $267.93 | 2020-2023 | |
| Puma Biotechnology, INC. | $267.56 | 2019-2025 | |
| Emd Serono, INC. | $234.73 | 2023-2025 | Bavencio |
| Array Biopharma INC | $230.19 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Alexion Pharmaceuticals, INC. | $211.74 | 2019-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $203.72 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.64 | 2023-2025 | Gilotrif |
| Seagen INC. | $175.20 | 2020-2023 | Tukysa, Adcetris, Padcev |
| Regeneron Healthcare Solutions, INC. | $157.37 | 2023-2025 | Libtayo |
| Karyopharm Therapeutics INC. | $139.89 | 2020-2025 | Xpovio |
| Kite Pharma, INC. | $134.36 | 2021-2025 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $117.98 | 2019-2024 | Somatuline Depot, Onivyde, Tazverik |
| Beone Medicines USA, INC. | $114.55 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $105.07 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $94.67 | 2023-2025 | Pyrukynd |
| Stemline Therapeutics INC. | $92.56 | 2019-2025 | Orserdu |
| Adaptive Biotechnologies Corporation | $86.35 | 2023-2024 | Clonoseq |
| Myovant Sciences INC. | $86.35 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $78.12 | 2023-2024 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $76.99 | 2023-2025 | Fotivda |
| Adc Therapeutics America, INC. | $76.76 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $76.03 | 2025 | Alymsys |
| Asd Specialty Healthcare, LLC | $66.63 | 2019 | |
| Coherus Oncology, INC. | $64.95 | 2024-2025 | Loqtorzi |
| Cardinal Health 108 LLC | $62.60 | 2022 | |
| Avyxa Pharma, LLC | $61.63 | 2025 | |
| Epizyme, INC. | $50.26 | 2021 | |
| Rigel Pharmaceuticals, INC. | $43.33 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Novocure INC. | $42.91 | 2025 | Optune Lua (Novottf-200t) |
| Mirati Therapeutics, INC. | $42.27 | 2023-2024 | Krazati |
| Boston Scientific Corporation | $39.43 | 2025 | Obsidio |
| Servier Pharmaceuticals LLC | $38.34 | 2025 | |
| Syndax Pharmaceuticals, INC. | $31.25 | 2025 | |
| Janssen Pharmaceuticals, INC | $29.51 | 2020-2021 | |
| Iovance Biotherapeutics, INC. | $28.75 | 2025 | Amtagvi |
| Immunogen, INC. | $25.86 | 2023 | Elahere |
| Dova Pharmaceuticals | $24.87 | 2021 | |
| Tactile Systems Technology INC | $24.16 | 2025 | Nimbl, Flexitouch Plus |
| Geron Corporation | $23.93 | 2025 | Rytelo |
| Helsinn Therapeutics (U.S.), INC. | $23.47 | 2019 | |
| Spectrum Pharmaceuticals INC. | $23.37 | 2025 | Rolvedon |
| Heron Therapeutics, INC. | $22.34 | 2022 | |
| Innate Pharma, INC | $20.94 | 2020 | |
| Amarin Pharma, INC. | $20.92 | 2019 | |
| Shire North American Group INC | $19.55 | 2019 | |
| Secura Bio, INC. | $19.12 | 2024 | Copiktra |
| Kyowa Kirin, INC. | $18.59 | 2025 | |
| Deciphera Pharmaceuticals INC. | $18.57 | 2024 | Qinlock |
| Exelixis INC. | $17.99 | 2019 | |
| Shield Therapeutics INC | $17.91 | 2025 | |
| Caris Mpi, INC. | $17.38 | 2025 | Mi Cancer Seek |
| Cumberland Pharmaceuticals, INC. | $15.79 | 2025 | Sancuso |
| Blue Earth Diagnostics | $15.53 | 2023 | |
| Tempus Ai, INC | $13.07 | 2024 |
Drugs and devices associated with these payments
Darzalex $612Imbruvica $568Jakafi $540Reblozyl $536Brukinsa $474Talvey $390Lenvima $378Besremi $294Scemblix $272Verzenio $266Tukysa $256Jaypirca $248Tecvayli $241Adcetris $221Vonjo $219Erleada $211Pomalyst $193Calquence $191Lynparza $190Trodelvy $189Rybrevant $179Enhertu $173Ojjaara $162Keytruda $160Braftovi $160Libtayo $157Ninlaro $155Opdivo $152Elrexfio $152Doptelet $151Bosulif $147Sarclisa $142Padcev $141Mektovi $131Zejula $125Lorbrena $118Akeega $115Balversa $115Iclusig $108Orgovyx $103Pyrukynd $94.67Imfinzi $92.61Ibrance $92.49Jemperli $90.22Clonoseq $86.35Stivarga $84.06Vitrakvi $84.06Welireg $83.56Synagis $80.60Inlyta $78.10Fotivda $76.99Alymsys $76.03Tecentriq $75.78Nubeqa $73.28Xtandi $71.81Lumakras $68.75Jevtana $67.99Xpovio $65.55Monjuvi $63.00Axtle $61.63Posfrea $61.63Lutrate Depot $61.63Docivyx $61.63Frindovyx $61.63Yescarta $56.01Elahere $52.83Pemazyre $52.75Talzenna $52.20Pluvicto $45.16Tavalisse $43.33Rezlidhia $43.33Loqtorzi $43.05Optune Lua (Novottf-200t) $42.91Krazati $42.27Kisqali $41.43Besponsa $40.56Monoferric $39.55Obsidio $39.43Somatuline Depot $39.31Onivyde $39.31Oxbryta $39.27Opdualag $38.54Tibsovo $38.34Xospata $37.94Piqray $36.01Orserdu $32.92Bavencio $31.54Emrelis $30.09Alunbrig $29.11Amtagvi $28.75Shingrix $28.30Lonsurf $27.25Inqovi $27.25Datroway $26.03Elitek $25.87Lutathera $25.59Tivdak $25.44Ultomiris $25.30Polivy $25.01Venclexta $24.80
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Labib Hashimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.